This week: New hope for people living with Huntington’s disease, and a report card on RFK Jr.’s effort to remake health in America.
The Food and Drug Administration reversed its opposition to a closely watched gene therapy for Huntington’s disease, clearing a path for its maker, the biotech company UniQure, to file for U.S. approval. Joining us to discuss ... Show More
May 28
403: Biotech exec Jeremy Levin on the industry's strategic turning point
On this week’s episode of “The Readout LOUD,” we chat with longtime biotech executive Jeremy Levin about his new book, “Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust.” That sounds alarmist, and it is in some respects, but as Levin explains, the book is ... Show More
47m 22s
Jun 2025
FDA ends GLP-1 compounding for semaglutide, tirzepatide
FDA’s removal of GLP-1 drugs from the shortage list ends supplemental compounding, shifting patient access back to branded semaglutide and tirzepatide. Featuring: Sara Heath, executive editor, Xtelligent Healthcare Alivia Kaylor, senior editor of Pharma Life Sciences, Xtelligent ... Show More
28m 22s
Feb 2025
Eli Lilly CEO: The Weight-Loss Drug Revolution, AI in Pharma, and Innovation
<p>Nicolai Tangen meets with David Ricks, CEO of Eli Lilly, for a discussion about the pharmaceutical giant's remarkable journey. At the forefront is Eli Lilly's breakthrough work with weight reduction drugs, which are showing promise far beyond their original ... Show More
55m 40s
Jun 2020
Market Surge, Treatment Hopes, Retail Sales, Royalty Pharma CEO, SoftBank’s T-Mobile Stake
<p>David Faber and Jim Cramer discuss the massive surge for stocks. Multiple reports emerging saying dexamethasone, a widely available drug, can help critically ill coronavirus patients. The treatment reportedly reduced Covid-19 deaths in hospitalized patients by up to one third. ... Show More
45m 4s
Aug 2024
Market Rally Aims for “Cloud Nine,” Bronfman's Paramount Bid, Eli Lilly CEO on Weight-Loss Drug 8/20/24
<p>Carl Quintanilla and Jim Cramer led off the show by delving into the broadening market rally, as the S&P 500 and Nasdaq aim for a ninth consecutive day of gains. David Faber called into the show with reporting on Edgar Bronfman's bid to acquire Paramount Global. Eli Lilly CEO ... Show More
44m 46s
Jul 2025
ICYMI: AstraZeneca Profit, Revenue Lifted by Cancer Drugs
AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer medicines and growth in the US.Revenue climbed 12% to $14.5 billion, the UK drugmaker said Tuesday, beating estimates. Earnings per share excluding some i ... Show More
14m 39s
Nov 2024
Roche CEO: Future of cancer treatment, AI in Medicine and Trial Challenges
<p>What’s next for cancer treatment and personalized medicine? How is AI reshaping the future of drug discovery? And can Europe keep pace with China’s rapid rise in health care innovation? In this episode, Nicolai welcomes Thomas Schinecker, CEO of Roche, one of the world’s large ... Show More
53m 58s
Jan 2025
AI, vaccine distrust, and the future of healthcare: Novartis CEO
Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis CEO Vas Narasimhan. Narasimhan has led the drug giant since 2018, doing deals that have expanded the company’s pipeline i ... Show More
25m 45s